Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

On December 12, 2022, Novozymes and Chr. Hansen announced that they have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

On March 30, 2023, Novozymes’ and Chr. Hansen’s shareholders approved the combination to create a leading global biosolutions partner. The completion of the proposed merger is subject to customary merger control and other regulatory approvals from relevant authorities.

Please see below for documents and other relevant information regarding the proposed merger.

Key documents

ANNOUNCEMENTS

PRESENTATIONS

Investor presentation Conference call

MERGER DOCUMENTS

Merger plan Merger statement Fairness opinion by financial advisor Auditor valuation expert statement on the contemplated merger Auditor creditor statement

EXEMPTION DOCUMENT AND RELATED DOCUMENTS

Exemption document (for Chr. Hansen shareholders residing in Australia) Exemption document (for other jurisdictions than Australia) Retail brochure FAQ Memorandum of Association dated October 1, 2004 Articles of Association dated November 23, 2022 Remuneration report 2021/22

EXTRAORDINARY GENERAL MEETING MARCH 30, 2023

Minutes Presentation Votes cast Resolutions passed Notice to convene Registration form Draft amended articles of association Number of shares and votes Processing of personal data in connection with the EGM Proxy/postal vote form Watch the EGM webcast

EKSTRAORDINÆR GENERALFORSAMLING 30. MARTS 2023

Referat Beslutninger truffet Indkaldelse til ekstraordinær generalforsamling Forslag til ændrede vedtægter Antal aktier og stemmer Behandling af persondata Fuldmagt/brevstemmeblanket Tilmeldingsblanket Se liveudsendelsen af vores ekstraordinære generalforsamling

CHR. HANSEN ANNUAL REPORTS

Chr. Hansen Annual report 2021/22 Chr. Hansen Annual report 2020/21 Chr. Hansen Annual report 2019/20

NOVOZYMES ANNUAL REPORTS

Novozymes annual report 2022 Novozymes annual report 2021 Novozymes annual report 2020 Novozymes annual report 2019

Contacts

Investor relations

Disa Tuominen

Investor Relations Manager

+45 60 38 58 26
[email protected]

Press relations

Lina Danstrup

Head of External Communications

+45 30 77 05 52
[email protected]

Restricted access

Access to this Website and the information contained herein is limited to persons resident:

in Denmark; OR
in Australia; OR
in the United States who are "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act of 1933, as amended ("Securities Act") pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and who have executed an investor letter; OR
outside Denmark, the United States, Canada, South Africa, Japan and any jurisdiction in which it would be unlawful to access any prospectus, exemption document or other offer materials published by Chr. Hansen in connection with the proposed transaction.